Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the ProfiLER progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassier, Philippe A., Peyramaure, Clémentine, Attignon, Valery, Eberst, Lauriane, Pacaud, Camille, Boyault, Sandrine, Desseigne, Françoise, Sarabi, Mathieu, Guibert, Pierre, Rochefort, Pauline, Marques, Nathalie, Rivoire, Michel, Dupré, Aurélien, Peyrat, Patrice, Terret, Catherine, Ray-Coquard, Isabelle, Coutzac, Clélia, Pérol, David, Blay, Jean-Yves, Trédan, Olivier, de la Fouchardière, Christelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605190/
https://www.ncbi.nlm.nih.gov/pubmed/34794033
http://dx.doi.org/10.1016/j.tranon.2021.101266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605190/
https://www.ncbi.nlm.nih.gov/pubmed/34794033
http://dx.doi.org/10.1016/j.tranon.2021.101266

Ejemplares similares